Imfinzi is a human monoclonal antibody that targets the PD-L1 protein, whereas Imjudo focuses on the CTLA-4 protein.

If the trial design doesn't cause regulatory issues, the results could reshape how muscle-invasive bladder tumors are treated.

AstraZeneca Plc’s Imfinzi extended the lives of patients with bladder cancer, potentially opening up a new market for the blockbuster medicine.

Imfinzi and chemotherapy before surgery, followed by Imfinzi after surgery, generated survival benefits in cisplatin-eligible muscle-invasive bladder cancer.

AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC) that it hopes will be enough to secure FDA approval – although the jury is out on that.

AstraZeneca’s Phase 3 study in bladder cancer, showed that giving Imfinzi — before and after surgery — cut the risk of death.